Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A thyroid gland carcinoma containing a medullary carcinoma component that is immunohistochemically positive for calcitonin, and follicular cell-derived carcinoma component that is immunohistochemically positive for thyroglobulin.
No clinical trials have been registered for thyroid gland mixed medullary and follicular cell-derived carcinoma.
3 publications have been identified in PubMed for thyroid gland mixed medullary and follicular cell-derived carcinoma. Research spans Case Report / Case Series (67%) and Review / Meta-Analysis (33%).
Cameselle-Teijeiro JM (2025). [PMID: 40102253](https://pubmed.ncbi.nlm.nih.gov/40102253/). *Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer*. [Review / Meta-Analysis]
Miyazaki S (2025). [PMID: 39839717](https://pubmed.ncbi.nlm.nih.gov/39839717/). *Journal of toxicologic pathology*. [Case Report / Case Series]
Prisneac I (2025). [PMID: 41283470](https://pubmed.ncbi.nlm.nih.gov/41283470/). *Pathophysiology : the official journal of the International Society for Pathophysiology*. [Case Report / Case Series]
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 9:33 PM UTC